Search over 3,000 reports

    Alpha- Antitrypsin Deficiency - Market Insights, Epidemiology and Market Forecast-2023

    Alpha- Antitrypsin Deficiency - Market Insights, Epidemiology and Market Forecast-2023
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 92
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0001
    DelveInsight's "Alpha- Antitrypsin Deficiency - Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Alpha- Antitrypsin Deficiency for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Alpha-Antitrypsin Deficiency from 2013-2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
    Scope
    - Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
    - Marketed information including available prescription drugs, its patent and exclusivity details.
    - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
    - It also provides Market size of Alpha-Antitrypsin Deficiency for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
    Report Introduction
    Alpha-Antitrypsin Deficiency Market Overview at a Glance
    Global Market Size of Alpha-Antitrypsin Deficiency in 2015
    Global Market Size of Alpha-Antitrypsin Deficiency in 2023
    Alpha-Antitrypsin Deficiency
    Overview
    Types
    Signs and symptoms
    Pathophysiology
    Risk Factors
    Diagnosis
    Treatment
    Epidemiology of Alpha-Antitrypsin Deficiency in 7MM
    United States
    Europe
    United Kingdom
    France
    Italy
    Germany
    Spain
    Japan
    Treatment Algorithm
    Current Unmet Needs
    Marketed Drugs
    Aralast NP : Shire
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Gemzar
    Product Profile
    Zemaira : CSL Behring
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Alimta
    Product Profile
    Glassia : Kamada
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Platinol
    Product Profile
    Prolastin C : Grifols
    Drug Description
    Mechanism of Action
    Regulatory Milestones
    Advantages & Disadvantages
    Safety and Efficacy of Paraplatin
    Product Profile
    Emerging Therapies
    Alpha-1 antitrypsin deficiency gene therapy : Applied Genetic Technologies
    Regulatory Milestones
    Advantages & Disadvantages
    Clinical Development
    Product Profile
    Clinical Pipeline Activity
    Ongoing Trials Information
    Clinical Trial by Phase
    Global Alpha-Antitrypsin Deficiency: Country-Wise Market Analysis
    Overview on Total Alpha-Antitrypsin Deficiency Market
    Total Market Size of Alpha-Antitrypsin Deficiency for 7 MM in 2013-2023
    United States
    Market Size of Alpha-Antitrypsin Deficiency in United States
    EU5
    Market Size of Alpha-Antitrypsin Deficiency in United Kingdom
    Market Size of Alpha-Antitrypsin Deficiency in Germany
    Market Size of Alpha-Antitrypsin Deficiency in France
    Market Size of Alpha-Antitrypsin Deficiency in Italy
    Market Size of Alpha-Antitrypsin Deficiency in Spain
    Japan
    Market Size of Alpha-Antitrypsin Deficiency in Japan
    Drivers
    Restraints
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Table 1: Prevalent Population of Alpha-Antitrypsin Deficiency in United States (2013-2023)
    Table 2: Prevalent Population of Alpha-Antitrypsin Deficiency in United Kingdom (2013-2023)
    Table 3: Prevalent Population of Alpha-Antitrypsin Deficiency in France (2013-2023)
    Table 4: Prevalent Population of Alpha-Antitrypsin Deficiency in Italy (2013-2023)
    Table 5: Prevalent Population of Alpha-Antitrypsin Deficiency in Germany (2013-2023)
    Table 6: Prevalent Population of Alpha-Antitrypsin Deficiency in Spain (2013-2023)
    Table 7: Prevalent Population of Alpha-Antitrypsin Deficiency in Japan (2013-2023)
    Table 8: Alpha-1 antitrypsin deficiency gene therapy, Clinical Trials by Zone, 2016
    Table 9: Clinical Trials by Recruitment status, 2016
    Table 10: Total Market size of Alpha-Antitrypsin Deficiency in USD Million (2013-2023)
    Table 11: United States Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Table 12: United Kingdom Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Table 13: Germany Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Table 14: France Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Table 15: Italy Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Table 16: Spain Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Table 17:Japan Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Figure 1: Prevalent Population of Alpha-Antitrypsin Deficiency in United States (2013-2023)
    Figure 2: Prevalent Population of Alpha-Antitrypsin Deficiency in United Kingdom (2013-2023)
    Figure 3: Prevalent Population of Alpha-Antitrypsin Deficiency in France (2013-2023)
    Figure 4: Prevalent Population of Alpha-Antitrypsin Deficiency in Italy (2013-2023)
    Figure 5: Prevalent Population of Alpha-Antitrypsin Deficiency in Germany (2013-2023)
    Figure 6: Prevalent Population of Alpha-Antitrypsin Deficiency in Spain (2013-2023)
    Figure 7: Prevalent Population of Alpha-Antitrypsin Deficiency in Japan (2013-2023)
    Figure 8: Alpha-1 antitrypsin deficiency gene therapy, Clinical Trials by Zone, 2016
    Figure 9: Clinical Trials by Recruitment status, 2016
    Figure 10: Total Market size of Alpha-Antitrypsin Deficiency in USD Million (2013-2023)
    Figure 11: United States Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Figure 12: United Kingdom Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Figure 13: Germany Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Figure 14: France Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Figure 15: Italy Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Figure 16: Spain Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Figure 17:Japan Market Size of Alpha-Antitrypsin Deficiency in USD, Million (2013-2023)
    Alpha- Antitrypsin Deficiency Market (7MM)

    Alpha- Antitrypsin Deficiency Market forecasting

    Alpha- Antitrypsin Deficiency Sales forecasting

    Alpha- Antitrypsin Deficiency Market segments

    Alpha- Antitrypsin Deficiency Epidemiology

    Alpha- Antitrypsin Deficiency Pipeline products and technologies

    Alpha- Antitrypsin Deficiency Competitive landscape

    Alpha- Antitrypsin Deficiency SWOT analysis

    Alpha- Antitrypsin Deficiency Market Driver's and barriers

    Alpha- Antitrypsin Deficiency Key Companies and Funding

    • Single User License
      (20% Off)
      $4,950.00
      $3960
    • Site License
      (30% Off)
      $9,900.00
      $6930
    • Global License
      (40% Off)
      $14,850.00
      $8910

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap